Heparin Reduces Neuroinflammation and Transsynaptic Neuronal Apoptosis in a Model of Subarachnoid Hemorrhage

Translational Stroke Research

Volumn 3, Issue SUPPL. 1, 2012, Pages 155-165

  Simard, J Marc ^a   Tosun, Cigdem ^a   Ivanova, Svetlana ^a   Kurland, David B ^a   Hong, Caron ^a   Radecki, Leanne ^a   Gisriel, Carter ^a   Mehta, Rupal ^a   Schreibman, David ^a   Gerzanich, Volodymyr ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Heparin; Microglia; Neuroinflammation; Rat; Subarachnoid hemorrhage; Transsynaptic apoptosis

Indexed keywords

CASPASE 3; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; CONTROLLED STUDY; DENTATE GYRUS; ENTORHINAL CORTEX; GRANULE CELL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SUBARACHNOID HEMORRHAGE; THERAPY DELAY; UPREGULATION;

EID: 84862248353     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0166-9     Document Type: Article

References (86)

1. Amiconi G, Zolla L, Vecchini P, et al. The effect of macromolecular polyanions on the functional properties of human hemoglobin. Eur J Biochem. 1977; 76: 339-43.
2. Ayer R, Jadhav V, Sugawara T, et al. The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2011; 111: 145-9.
3. Bauer J, Sminia T, Wouterlood FG, et al. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res. 1994; 38: 365-75.
4. Berry CN, Girard D, Lochot S, et al. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol. 1994; 113: 1209-14.
5. Bhardwaj A. Molecular targets for ameliorating early brain injury post subarachnoid hemorrhage: a new focus. Crit Care Med. 2010; 38: 727-8.
6. Buchanan KM, Elias LJ, Goplen GB. Differing perspectives on outcome after subarachnoid hemorrhage: the patient, the relative, the neurosurgeon. Neurosurgery. 2000; 46: 831-8.
7. Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006; 26: 1341-53.
8. Cahill J, Zhang JH. Subarachnoid hemorrhage: is it time for a new direction? Stroke. 2009; 40: S86-7.
9. Casu B. Structure of heparin and heparin fragments. Ann N Y Acad Sci. 1989; 556: 1-17.
10. Chahal N, Barker-Collo S, Feigin V. Cognitive and functional outcomes of 5-year subarachnoid haemorrhage survivors: comparison to matched healthy controls. Neuroepidemiology. 2011; 37: 31-8.
11. Chaichana KL, Pradilla G, Huang J, et al. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. World Neurosurg. 2010; 73: 22-41.
12. Chansel D, Ciroldi M, Vandermeersch S, et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J. 2006; 20: 1936-8.
13. Chew DJ, Carlstedt T, Shortland PJ. A comparative histological analysis of two models of nerve root avulsion injury in the adult rat. Neuropathol Appl Neurobiol. 2011; 37: 613-32.
14. Coombe DR. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol. 2008; 86: 598-607.
15. Dijkstra CD, Dopp EA, Joling P, et al. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology. 1985; 54: 589-99.
16. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011; 41: 1203-17.
17. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery. 2003; 53: 123-33.
18. Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003; 15: 11-8.
19. Endo H, Nito C, Kamada H, et al. Reduction in oxidative stress by superoxide dismutase overexpression attenuates acute brain injury after subarachnoid hemorrhage via activation of Akt/glycogen synthase kinase-3beta survival signaling. J Cereb Blood Flow Metab. 2007; 27: 975-82.
20. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999; 85: 257-72.
21. Etminan N, Vergouwen MD, Ilodigwe D, et al. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011; 31: 1443-51.
22. Friedrich V, Flores R, Muller A, et al. Reduction of neutrophil activity decreases early microvascular injury after subarachnoid haemorrhage. J Neuroinflammation. 2011; 8: 103.
23. Fryer A, Huang YC, Rao G, et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther. 1997; 282: 208-19.
24. Gallia GL, Tamargo RJ. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. Neurol Res. 2006; 28: 750-8.
25. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des. 2008; 72: 455-82.
26. Gerzanich V, Ivanov A, Ivanova S, et al. Alternative splicing of cGMP-dependent protein kinase I in angiotensin-hypertension: novel mechanism for nitrate tolerance in vascular smooth muscle. Circ Res. 2003; 93: 805-12.
27. Ginsberg SD, Martin LJ. Axonal transection in adult rat brain induces transsynaptic apoptosis and persistent atrophy of target neurons. J Neurotrauma. 2002; 19: 99-109.
28. Graeber MB, Lopez-Redondo F, Ikoma E, et al. The microglia/macrophage response in the neonatal rat facial nucleus following axotomy. Brain Res. 1998; 813: 241-53.
29. Hanafy KA, Morgan SR, Fernandez L, et al. Cerebral inflammatory response and predictors of admission clinical grade after aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2010; 17: 22-5.
30. Hanel RA, Xavier AR, Mohammad Y, et al. Outcome following intracerebral hemorrhage and subarachnoid hemorrhage. Neurol Res. 2002; 24 Suppl 1: S58-62.
31. Hansen-Schwartz J, Vajkoczy P, Macdonald RL, et al. Cerebral vasospasm: looking beyond vasoconstriction. Trends Pharmacol Sci. 2007; 28: 252-6.
32. Hiebert LM, Wice SM, McDuffie NM, et al. The heparin target organ-the endothelium. Studies in a rat model. Q J Med. 1993; 86: 341-8.
33. Higashiyama S, Iwabuki H, Morimoto C, et al. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008; 99: 214-20.
34. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta. 2005; 1751: 110-7.
35. Hirano K, Hirano M. Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J Pharmacol Sci. 2010; 114: 127-33.
36. Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001; 21: 1094-6.
37. Ishikawa M, Kusaka G, Yamaguchi N, et al. Platelet and leukocyte adhesion in the microvasculature at the cerebral surface immediately after subarachnoid hemorrhage. Neurosurgery. 2009; 64: 546-53.
38. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998; 50: 1413-8.
39. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001; 947: 42-54.
40. Kovac AD, Kwidzinski E, Heimrich B, et al. Entorhinal cortex lesion in the mouse induces transsynaptic death of perforant path target neurons. Brain Pathol. 2004; 14: 249-57.
41. Kuwahara-Watanabe K, Hidai C, Ikeda H, et al. Heparin regulates transcription of endothelin-1 gene in endothelial cells. J Vasc Res. 2005; 42: 183-9.
42. Laohaprasit V, Mayberg MR. Risks of anticoagulation therapy after experimental corticectomy in the rat. Neurosurgery. 1993; 32: 625-8.
43. Lee JY, Keep RF, He Y, et al. Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab. 2010; 30: 1793-803.
44. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov. 2002; 1: 140-8.
45. Lindahl U, Lidholt K, Spillmann D, et al. More to "heparin" than anticoagulation. Thromb Res. 1994; 75: 1-32.
46. Ling Y, Yang ZY, Yin T, et al. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int Immunopharmacol. 2011; 11: 187-93.
47. Liu R, Mori S, Wake H, et al. Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama. 2009; 63: 203-11.
48. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011; 10: 618-25.
49. Matz PG, Copin JC, Chan PH. Cell death after exposure to subarachnoid hemolysate correlates inversely with expression of CuZn-superoxide dismutase. Stroke. 2000; 31: 2450-9.
50. Matz PG, Fujimura M, Chan PH. Subarachnoid hemolysate produces DNA fragmentation in a pattern similar to apoptosis in mouse brain. Brain Res. 2000; 858: 312-9.
51. Mulloy B. The specificity of interactions between proteins and sulfated polysaccharides. An Acad Bras Cienc. 2005; 77: 651-64.
52. Murakami K, Koide M, Dumont TM, et al. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res. 2011; 2: 72-9.
53. Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 2006; 55: 2510-22.
54. Nau R, Haase S, Bunkowski S, et al. Neuronal apoptosis in the dentate gyrus in humans with subarachnoid hemorrhage and cerebral hypoxia. Brain Pathol. 2002; 12: 329-36.
55. Niikawa S, Kitajima H, Ohe N, et al. Significance of acute cerebral swelling in patients with sylvian hematoma due to ruptured middle cerebral artery aneurysm, and its management. Neurol Med Chir (Tokyo). 1998; 38: 844-8.
56. Nomura Y, Kawaguchi M, Yoshitani K, et al. Retrospective analysis of predictors of cerebral vasospasm after ruptured cerebral aneurysm surgery: influence of the location of subarachnoid blood. J Anesth. 2010; 24: 1-6.
57. Olson ST, Bjork I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992; 267: 12528-38.
58. Ostrowski RP, Colohan AR, Zhang JH. Mechanisms of hyperbaric oxygen-induced neuroprotection in a rat model of subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2005; 25: 554-71.
59. Park S, Yamaguchi M, Zhou C, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004; 35: 2412-7.
60. Patel AD, Gerzanich V, Geng Z, et al. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol. 2010; 69: 1177-90.
61. Pradilla G, Chaichana KL, Hoang S, et al. Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin N Am. 2010; 21: 365-79.
62. Provencio JJ, Fu X, Siu A, et al. CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage. Neurocrit Care. 2010; 12: 244-51.
63. Prunell GF, Svendgaard NA, Alkass K, et al. Delayed cell death related to acute cerebral blood flow changes following subarachnoid hemorrhage in the rat brain. J Neurosurg. 2005; 102: 1046-54.
64. Prunell GF, Svendgaard NA, Alkass K, et al. Inflammation in the brain after experimental subarachnoid hemorrhage. Neurosurgery. 2005; 56: 1082-92.
65. Rao NV, Argyle B, Xu X, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol. 2010; 299: C97-110.
66. Rider CC. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans. 2006; 34: 458-60.
67. Robinson MJ, Tessier P, Poulsom R, et al. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem. 2002; 277: 3658-65.
68. Sabri M, Kawashima A, Ai J, et al. Neuronal and astrocytic apoptosis after subarachnoid hemorrhage: a possible cause for poor prognosis. Brain Res. 2008; 1238: 163-71.
69. Savaskan NE, Eyupoglu IY, Brauer AU, et al. Entorhinal cortex lesion studied with the novel dye Fluoro-Jade. Brain Res. 2000; 864: 44-51.
70. Schmued LC, Stowers CC, Scallet AC, et al. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 2005; 1035: 24-31.
71. Scholz J, Broom DC, Youn DH, et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci. 2005; 25: 7317-23.
72. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol. 2002; 88: 227-49.
73. Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009; 29: 317-30.
74. Simard JM, Schreibman D, Aldrich EF, et al. Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. Neurocrit Care. 2010; 13: 439-49.
75. Simard JM, Yurovsky V, Tsymbalyuk N, et al. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009; 40: 604-9.
76. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999; 9: 69-92.
77. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice. Stroke. 2009; 40: 2519-25.
78. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Immunological response in early brain injury after SAH. Acta Neurochir Suppl. 2011; 110: 57-61.
79. Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2000; 278: H2084-93.
80. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995; 16: 198-204.
81. Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002; 110: 127-36.
82. Wang L, Shi JX, Yin HX, et al. The influence of subarachnoid hemorrhage on neurons: an animal model. Ann Clin Lab Sci. 2005; 35: 79-85.
83. Weiler JM, Edens RE, Linhardt RJ, et al. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992; 148: 3210-5.
84. Wu Y, Tang K, Huang RQ, et al. Therapeutic potential of peroxisome proliferator-activated receptor gamma agonist rosiglitazone in cerebral vasospasm after a rat experimental subarachnoid hemorrhage model. J Neurol Sci. 2011; 305: 85-91.
85. Yokokawa K, Mandal AK, Kohno M, et al. Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am J Physiol. 1992; 263: R1035-41.
86. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008; 122: 743-52.